An integrated model system to gain mechanistic insights into biofilm-associated antimicrobial resistance in *Pseudomonas aeruginosa* MPAO1

Adithi R. Varadarajan1,11, Raymond N. Allan2,3,4,11, Jules D. P. Valentín5,6,11, Olga E. Castañeda Ocampo6, Vincent Somerville1, Franziska Pietsch2, Matthias T. Buhmann2, Jonathan West2,9, Paul J. Skipp10, Henny C. van der Mei5, Qun Ren6, Frank Schreiber7, Jeremy S. Webb2,3 and Christian H. Ahrens6,15

**Pseudomonas aeruginosa** MPAO1 is the parental strain of the widely utilized transposon mutant collection for this important clinical pathogen. Here, we validate a model system to identify genes involved in biofilm growth and biofilm-associated antibiotic resistance. Our model employs a genomics-driven workflow to assemble the complete MPAO1 genome, identify unique and conserved genes by comparative genomics with the PAO1 reference strain and genes missed within existing assemblies by proteogenomics. Among over 200 unique MPAO1 genes, we identified six general essential genes that were overlooked when mapping public Tn-seq data sets against PAO1, including an antitoxin. Genomic data were integrated with phenotypic data from an experimental workflow using a user-friendly, soft lithography-based microfluidic flow chamber for biofilm growth and a screen with the Tn-mutant library in microtitre plates. The screen identified hitherto unknown genes involved in biofilm growth and antibiotic resistance. Experiments conducted with the flow chamber across three laboratories delivered reproducible data on *P. aeruginosa* biofilms and validated the function of both known genes and genes identified in the Tn-mutant screens. Differential protein abundance data from planktonic cells versus biofilm confirmed the upregulation of candidates known to affect biofilm formation, of structural and secreted proteins of type VI secretion systems, and provided proteogenomic evidence for some missed MPAO1 genes. This integrated, broadly applicable model promises to improve the mechanistic understanding of biofilm formation, antimicrobial tolerance, and resistance evolution in biofilms.

npj Biofilms and Microbiomes (2020) 6:46; https://doi.org/10.1038/s41522-020-00154-8

**INTRODUCTION**

*Pseudomonas aeruginosa* is a Gram-negative bacterium ubiquitously present in the soil, water, and different animal hosts. As an opportunistic human pathogen, it can cause sepsis, and chronic wound and lung infections, especially in immunocompromised and cystic fibrosis patients. Two mechanisms complicate the treatment of *P. aeruginosa* infections. It forms recalcitrant biofilms in which the bacterial cells have an increased tolerance against antimicrobial compounds. In addition, worldwide, multiple genetic variants have acquired antimicrobial resistance (AMR) traits, either through the acquisition of resistance genes on mobile genetic elements such as plasmids or through de novo mutations of chromosomal genes. Furthermore, mutations affecting outer membrane porins and multidrug efflux pumps can mediate resistance to almost all major antibiotic classes and several important biocides. *P. aeruginosa* thus also belongs to the notorious group of ESKAPE pathogens, which represent the leading causes of worldwide nosocomial infections (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, and *Enterobacter species*). Clinically most relevant are the resistances of *P. aeruginosa* strains against fluoroquinolones, aminoglycosides, and beta-lactams, and against the last-resort antibiotic colistin (polymyxin). In 2017, the World Health Organization (WHO) classified carbapenem-resistant *P. aeruginosa* strains in the highest priority group of “critical pathogens”. New treatment options informed by a more detailed molecular understanding of how and why resistance emerges during treatment, and how resistance is transmitted, are urgently needed for such critical pathogens.

Increased antimicrobial tolerance, a fundamental property of biofilms, is well-studied and four mechanisms have a major role: (i) under nutrient-limited conditions in biofilms, *P. aeruginosa* expresses phenotypic variants, i.e., dormant cells that are less susceptible to antibiotics which target actively dividing cells; (ii) *P. aeruginosa* form a protective extracellular matrix composed of polysaccharides, proteins, and DNA that limits the diffusion of antimicrobial substances or sequesters them, such that biofilm cells experience a decreased antimicrobial dosage; (iii) anoxic conditions exist within the biofilm limiting the efficacy of antibiotics that require aerobic metabolic activity and the generation of reactive oxygen species; (iv) sub-inhibitory concentrations of antibiotics induce increased rates of mutation, }

---

1Research Group Molecular Diagnostics Genomics & Bioinformatics, Agroscope and SIB Swiss Institute of Bioinformatics, Wädenswil, Switzerland. 2School of Biological Sciences and Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK. 3National Biofilms Innovation Centre, University of Southampton, Southampton SO17 1BJ, UK. 4School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, Leicester LE1 9BH, UK. 5Laboratory for Biointerfaces, Empa, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen, Switzerland. 6Department of BioMedical Engineering, University of Groningen and University Medical Center Groningen, Groningen, Netherlands. 7Division of Biodeterioration and Reference Organisms, Federal Institute for Materials Research and Testing (BAM), Berlin, Germany. 8Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK. 9Centre for Hybrid Biodevices, University of Southampton, Southampton SO17 1BJ, UK. 10Centre for Proteomics Research, University of Southampton, Southampton SO17 1BI, UK. 11These authors contributed equally: Adithi R. Varadarajan, Raymond N. Allan, Jules D. P. Valentín. 12email: vadithi.ethz@gmail.com; christian.ahrens@agroscope.admin.ch

Published in partnership with Nanyang Technological University
recombination, and lateral gene transfer. The mutation rate in biofilms has been reported to be up to 100 times higher than in planktonic cells\(^1\), significantly accelerating the development of antibiotic-resistant mutants. Together, these mechanisms lead to hard-to-treat, chronic infections during which *P. aeruginosa* can persist and further evolve within the host in the presence of antimicrobial substances. Evolution within biofilms is highly parallel and differs significantly from the evolution of planktonic cells\(^2\). However, the evolutionary drivers of within-biofilm AMR evolution remain poorly understood. Their study requires well-defined model systems and tools, including model strains with complete genomic background information, genetic tools, and flow chambers allowing representative and reproducible growth of *P. aeruginosa* biofilms and deep sequencing data\(^3\).

The canonical reference strain for *P. aeruginosa* is PAO1, also referred to as PAO1-UW. Its complete genome sequence was published in 2000\(^4\), which allowed many breakthrough discoveries. However, a number of closely related PAO1 strains exist that differ in their phenotypic appearances\(^5\). These include *P. aeruginosa* strain MPAO1\(^6\), the parental strain of the widely used transposon insertion mutant library from the University of Washington (UW)\(^7\). Such mutant collections represent highly valuable resources to uncover new functions and condition-specific essential genes in genome-wide screens\(^8\), for example, genes relevant for resistance against certain antibiotics\(^9,10\). They have also been used to define so-called general essential genes, i.e., genes that were identified as essential under more than one relevant growth condition\(^11,12\). As a subset of the conserved core genes of *P. aeruginosa* PAO1 and PA14 were shown to exhibit differential essentiality\(^13\). The approach to focus on those general essential genes that are furthermore conserved among key pathogen strains of a species is particularly promising\(^14\). However, the utility of such libraries to identify gain of function mutations is limited and polar effects need to be controlled for\(^15\). Notably, no complete MPAO1 genome sequence was available, improvements in next-generation sequencing (NGS) technologies\(^16\) and assembly algorithms nowadays allow researchers to readily generate complete de novo genome assemblies for most prokaryotes except a few percent of strains with highly complex repeat regions\(^17\). Such fully resolved genomes are advantageous compared to fragmented short read-based genome assemblies that can sometimes even miss conserved core genes\(^18\); they are an ideal basis for subsequent functional genomics and systems biology studies and allow researchers to identify so far missed genes in genome annotations by proteogenomics\(^19\).

Here, we set out to develop, validate, and make available a model system to study the biofilm-associated adaptation to antimicrobials and AMR evolution in *P. aeruginosa* MPAO1. Conceptually, the model was designed to integrate genotype information with phenotypic data and to leverage the valuable genetic tools and wealth of functional genomics data sets that exist for important bacterial model organisms. Important elements include the complete MPAO1 genome sequence and the design for a standardized flow chamber based on accessible soft-lithography replication in poly(dimethylsiloxane) (PDMS) that can deliver laminar flow conditions relevant to typical biofilm niches. Comparative genomics with the PAO1-UW reference strain uncovered numerous MPAO1-unique genes. Strikingly, these included 39 essential genes that had been missed so far by performing reference-based mapping of public Tn-seq data sets. Proof of principle experiments highlighted reproducible biofilm growth using the microfluidic flow chamber and identified hitherto unknown genes important for biofilm growth and biofilm-associated AMR through microtiter plate screening of the mutant library. A differential (planktonic vs. biofilm) proteomic data set uncovered gene products known to have a role in biofilm formation. Finally, a publicly available, integrated proteogenomics search database enables the identification of unannotated genes in MPAO1.

**RESULTS**

De novo genome assembly of MPAO1

The availability of a complete genome sequence is an important pre-requisite to study the phenotypic adaptation and evolution of resistance to antimicrobials in biofilms. An analysis of over 9300 completely sequenced, publicly available bacterial genomes\(^20\) (see “Methods” section) listed 106 *P. aeruginosa* strains overall, two of which were *P. aeruginosa* PAO1 strains, including the PAO1 type strain (Genbank AE004091), also called PAO1-UW\(^21\). In contrast, the only strain annotated as MPAO1, i.e., the founder strain of the transposon mutant library available from the UW\(^22\), had been sequenced with Illumina short reads, assembled into 140 contigs and deposited (http://www.pseudomonas.com/strain/show?Id=659; Genbank ASM24743v2) in the Pseudomonas genome DB\(^23\). To provide an optimal basis for subsequent functional genomics and evolution studies for *P. aeruginosa* strain MPAO1, we thus first sequenced and de novo assembled its complete genome. Due to the genomic differences reported for MPAO1 and PAO1\(^24\) and the fact that many of the 106 completely sequenced *P. aeruginosa* strains have difficult to assemble genomes with long repeat pairs in excess of 10 kilobases (kb) (38/106), so-called class III genomes\(^25\), we used third-generation long reads from PacBio RSII platform. By relying on size-selected fragments (average length 9 kb; see “Methods” section), a single bacterial chromosome could be assembled. Additional genome polishing steps with Illumina MiSeq data (300 bp, PE reads) allowed the removal of remaining homopolymer errors in the PacBio assembly\(^26\). The final, high-quality MPAO1 genome consisted of one chromosome of 6,275,467 bp and coded for 5926 genes (Genbank CP027857; Table 1). An overview of selected predicted genome features (see “Methods” section) is shown in Supplementary Table 1. To facilitate data mining and comparison, we also provide an extensive annotation of all 5799 protein-coding genes. This includes information on conserved and MPAO1-unique genes compared to PAO1, the respective reciprocal best BLAST hits, protein domains, families, Gene Ontology (GO) classification, predictions of subcellular localization, lipoproteins, secreted and described membrane-localized proteins, as well as gene essentiality status and protein abundance data below (Supplementary Data 1).

Comparative genomics of MPAO1 and PAO1 strains

An alignment of our de novo assembled MPAO1 genome with that of the MPAO1/P1 strain\(^27\) revealed that overall, 42,813 bp of

| Category | *P. aeruginosa* MPAO1 | *P. aeruginosa* PAO1-UW |
|----------|-----------------------|-------------------------|
| Total no. of genes | 5926 | 5697 |
| Total no. of CDS | 5799 | 5572 |
| No. of core CDS (clusters\(^a\)) | 5548 (5534) | 5545 (5534) |
| No. of unique (strain-specific) CDS (clusters) | 234 (232) | 19 (21) |
| Unique ncRNA | 3 | |
| CDS ≤ 120 bp\(^b\) | 17 | 5 |

\(^a\)All individual CDS are shown including those that are grouped in gene clusters (paralogs) in Fig. 1c.

\(^b\)CDS of 120 bp or below are not considered (see “Methods” section).
Fig. 1 Genome map of P. aeruginosa MPAO1 and comparison to other strains. a The Circos plot visualizes the comparison of our complete MPAO1genome (outer circle with genome coordinates) and that of strain MPAO1/P1 (second circle; blue), the respective gaps (third circle; blue) followed by annotated prophages (fourth circle; purple), missing genes (fifth circle, red), pseudogenes (sixth circle; brown), and GC skew (seventh circle; positive - purple; negative - green). b Differences of the MPAO1 genome compared to the PAO1 reference strain. Going from outer towards inner circles, the following genome features are shown: (1) a large inversion (gray) flanked by rRNAs (not shown), (2) SNPs (dark orange), (3) INDELs (light orange) (4) prophages (purple), (5) genes unique to MPAO1 (blue). c Comparative genomic analysis of P. aeruginosa strains MPAO1 and PAO1-UW. The Venn diagram shows the core gene clusters (paralogous genes are grouped into the same cluster provided they belong to a syntenic genomic region) and the respective number of strain-specific CDS clusters.

The complete MPAO1 genome sequence allowed us to re-analyze public Tn-seq data sets without the limitation of any remaining "genomic blind spots" that otherwise might preclude...
identification of all essential genes, and the drawbacks of mapping Tn-seq data to a closely related reference genome. A re-mapping of MPAO1 Tn-seq data sets obtained from several conditions (LB medium, minimal medium, sputum, and brain-heart infusion BHI medium) against both the PAO1-UW genome and our MPAO1 genome (see “Methods” section), confirmed our expectation. We indeed observed a higher percentage of mapped reads for MPAO1 (roughly 0.1–0.35% of all mapped reads per sample; Supplementary Table 3) and unique insertion sites (roughly 0.2% more in MPAO1, Supplementary Table 3). Genes with no insertion or genes whose p-value was less than 0.001 were considered essential (see "Methods" section). Overall, 577 genes were classified as condition-specific essential in one of the three primary growth conditions LB medium, minimal medium, sputum (Supplementary Data 4), and 312 genes represented general essential genes, i.e., were essential in all three growth conditions, respectively (Supplementary Fig. 2). Importantly, close to 40 MPAO1 unique genes were linked here with an essentiality status, as they were essential in one or more of the 16 Tn-seq libraries (Supplementary Data 4). By mapping data against the PAO1-UW genome, these genes had been previously overlooked in the analysis of essential P. aeruginosa genes.

Among these MPAO1-unique genes, we identified 18 genes that were essential in 50% or more of the Tn-seq runs, six of which represented general essential genes (Table 2). The general essential genes included two genes located in the prophage 2 region, i.e., MPA01_22380, a type II Phd/YefM family antitoxin gene located next to MPA01_22375, coding for a RelE/ParE type toxin, and MPA01_22450, a DNA-binding protein (Fig. 2a; arrows framed in red). A further general essential gene was MPA01_00215 encoding for a hypothetical protein. MPA01_00215 is located in a genomic region that harbors another essential gene (MPAO1_00230, Supplementary Data 1), that may represent an operon.

Furthermore, the prophage 3 region unique to strain MPAO1, harbored a gene encoding a hypothetical protein (MPAO1_24865; Fig. 2b) that was essential in eight of 16 samples (Table 2). Conversely, MPA01_24885 (addiction module antitoxin protein from the HigA family toxin-antitoxin (TA) system) from this region was classified as general essential (Table 2; 14 of 16 samples). Due to its homology to PA4674 in PAO1-UW, which is listed among the 352 general essential genes reported by Lee and colleagues and encodes the HigA antitoxin, it is not unique to MPA01 (Fig. 2b).

Together with the non-essential MPAO1_24890 (plasmid maintenance system killer protein; most similar to RelE-like toxins of the type II TA system HigB), MPA01_24885 encodes for a TA system. However, there is no homolog annotated for MPA01_24890 in PAO1-UW. Therefore, due to this missing gene, the TA system was not identified in PAO1-UW. This finding again underlines the importance of having the actual and complete genome sequence to map functional data.

Reproducible formation of MPAO1 biofilms

The second important objective of our integrated model system was to enable the reliable generation of phenotypic data under conditions relevant for biofilm growth. For this purpose, we focused on the development of a microfluidic flow chamber for reproducible biofilm formation that would allow us to subsequently identify genes relevant for biofilm growth and biofilm-associated AMR. The flow chamber was designed in such a way that we could assess the effects of hydrodynamic conditions, such as shear stress and controlled flow conditions. Our flow chamber was replicated in PDMS, a simple to use, transparent, and breathable elastomer material that naturally adheres to the glass. A straight microfluidic channel design was used (30 mm length × 2 mm width × 0.200 mm depth) (Fig. 3a, see “Methods” section for further details). PDMS was selected due to its broad application in indwelling devices and implant materials. The inlet and outlet of the microfluidic flow chamber comprised of sterile polytetrafluoroethylene (PTFE) tubing, a material that was chosen because it generally exhibits low bacterial adhesion. A syringe pump was used to deliver 5 μL/min (u = 208 μm/s) flow inside the chamber to provide laminar flow conditions for bacterial adhesion and biofilm growth (the calculated Reynolds Number corrected for the

Table 2. List of 18 selected MPAO1-unique genes along with their essentiality classification in all 16 Tn-seq samples and comments about their genomic location.

| Locus     | Gene annotation                                      | General essential | Essential in x/16 samples | Comment             |
|-----------|------------------------------------------------------|-------------------|---------------------------|---------------------|
| MPAO1_22380 | Type II toxin-antitoxin system Phd/YefM family antitoxin | Yes               | 16                         | Prophage 2          |
| MPAO1_00215 | Hypothetical protein                                  | Yes               | 15                         | *Operon?            |
| MPAO1_10410 | Hypothetical protein                                  | Yes               | 14                         |                     |
| MPAO1_22450 | DNA-binding protein                                   | Yes               | 14                         | Prophage 2          |
| MPAO1_25260 | Cytidine deaminase                                    |                   |                            |                     |
| MPAO1_12950 | Hypothetical protein                                  | Yes               | 11                         |                     |
| MPAO1_00230 | Hypothetical protein                                  |                   |                            |                     |
| MPAO1_20095 | Hypothetical protein                                  |                   |                            |                     |
| MPAO1_02335 | Dihydropyrimidinase                                   |                   |                            |                     |
| MPAO1_15010 | 6-O-methylguanine DNA methyltransferase               |                   |                            |                     |
| MPAO1_15215 | Amino acid permease                                   |                   |                            |                     |
| MPAO1_18025 | Ferredoxin                                            |                   |                            |                     |
| MPAO1_02315 | Oxidoreductase                                        |                   |                            |                     |
| MPAO1_05695 | Hypothetical protein                                  | Yes               | 8                          | Bacteriocin (GO)    |
| MPAO1_08710 | DUF3304 domain-containing protein                     |                   |                            |                     |
| MPAO1_10195 | Universal stress protein                              |                   |                            |                     |
| MPAO1_14380 | Glycosyltransferase                                   |                   |                            |                     |
| MPAO1_22450 | Hypothetical protein                                  |                   |                            |                     |
| MPAO1_22380 | Type II toxin-antitoxin system Phd/YefM family antitoxin | Yes               | 16                         | Prophage 2          |
| MPAO1_00215 | Hypothetical protein                                  | Yes               | 15                         | *Operon?            |
| MPAO1_10410 | Hypothetical protein                                  | Yes               | 14                         |                     |
| MPAO1_22450 | DNA-binding protein                                   | Yes               | 14                         | Prophage 2          |
| MPAO1_25260 | Cytidine deaminase                                    |                   |                            |                     |
| MPAO1_12950 | Hypothetical protein                                  | Yes               | 11                         |                     |
| MPAO1_00230 | Hypothetical protein                                  |                   |                            |                     |
| MPAO1_20095 | Hypothetical protein                                  |                   |                            |                     |
| MPAO1_02335 | Dihydropyrimidinase                                   |                   |                            |                     |
| MPAO1_15010 | 6-O-methylguanine DNA methyltransferase               |                   |                            |                     |
| MPAO1_15215 | Amino acid permease                                   |                   |                            |                     |
| MPAO1_18025 | Ferredoxin                                            |                   |                            |                     |
| MPAO1_02315 | Oxidoreductase                                        |                   |                            |                     |
| MPAO1_05695 | Hypothetical protein                                  | Yes               | 8                          | Bacteriocin (GO)    |
| MPAO1_08710 | DUF3304 domain-containing protein                     |                   |                            |                     |
| MPAO1_10195 | Universal stress protein                              |                   |                            |                     |
| MPAO1_14380 | Glycosyltransferase                                   |                   |                            |                     |
| MPAO1_22450 | Hypothetical protein                                  |                   |                            |                     |
transport of water at 37 °C was 0.103; for details see Supplementary Table 4).

The reproducibility of a 72 h mature MPAO1 biofilm on the PDMS surface of the device was investigated by confocal laser scanning microscopy (CLSM) combined with live/dead staining using the dyes Syto9 and propidium iodide in three separate consortium laboratories all using the same microfluidic chamber mold (design publicly available; see Data availability) (Fig. 3b, c). The biofilms formed in the three laboratories were consistent with data falling within 95% confidence intervals, the only difference being the observation of a reduced dead biovolume in one laboratory’s model (Lab A; p value < 0.05). Biofilm formation was relatively uniform throughout the flow channel with an average thickness of 16 µm and a small reduction observed towards the center of the channel (Inlet—18.8 µm, 25%—15.8 µm, 50%—13.3 µm, 75%—14.9 µm, Outlet—17.3 µm). An average biovolume of 12.5 µm³/µm² and dead biovolume of 8.4 µm³/µm² was observed, again reducing towards the center of the device commensurate with the average biomass.

Screening experiments identify known and new genes relevant for biofilm formation and antibiotic resistance

The MPAO1 transposon mutant library was tested with a 96-well plate screening system that was devised to enable the identification of genes that affect biofilm formation and/or have a role in the development of biofilm-associated AMR (see Supplementary Fig. 3). A batch of 95 selected mutants (Supplementary Table 5) was taken from the library to test the reliability of our protocol and to identify genes related to biofilm formation (in duplicate). Strain PW8965 harboring an insertion in cbrB (PAO1 identifier PA4726, MPAO1_25185), a transcriptional activator that forms part of the CbrA/CbrB two-component system important in catabolite repression37, was found to produce the least amount of biofilm (Fig. 4a).

In contrast, strain PW9283 mutated in pntAA (PA0195; MPAO1_01040), an NADPH/NAD⁺ redox balance transhydrogenase38, exhibited the highest biofilm biomass.

In a second step, selected mutants identified by the screening and the proteomic analysis (see below) were compared to positive and negative controls for biofilm formation (Fig. 5a). The pslB
Fig. 3  The publicly available mold design for the microfluidic flow chamber allows reproducible biofilm formation as confirmed by an inter-laboratory comparison.  

**a** Schematic and dimensions of the flow chamber.  

**b** Representative images of 72 h MPAO1 WT biofilms grown on the PDMS surface of the device under laminar flow conditions at five different locations along the channel. Biofilms were treated with live/dead staining (green – live cells stained with Syto9; red – dead cells stained with propidium iodide). Scale bar in confocal XY plane: 40 µm. Sagittal XZ section represents biofilm thickness.  

**c** COMSTAT data for average thickness, and live/dead biovolume of 72 h MPAO1 WT biofilms generated by three different laboratories, with 95% confidence interval comparisons (3 biological repeats comprising 3 technical repeats per site, i.e., n = 9 biological/n = 27 technical repeats overall; error bars - standard error of mean; 2-way ANOVA with lab and channel location as variables followed by multiple comparisons Tukey test). *p value < 0.05.
Fig. 4  Proof of principle that biofilm growth-relevant and AMR-related genes can be identified in adequate screens using the MPAO1 transposon mutant library. A diagram of the protocol is shown in Supplementary Fig. 3. **a** Biofilm formation of 90 MPAO1 mutant strains (X axis) after 24 h incubation in the M9 medium (average of two independent wells). Biofilm biomass was quantified by crystal violet. **b** Ability of biofilms formed by 90 MPAO1 mutant strains to recover after colistin treatment (see “Methods” section). The recovery of treated biofilm cells was normalized to the recovery of non-treated biofilm cells (defined as 100%). The *arnB* mutant (PA3552) is highlighted in red, as well as the highest biofilm former missing *pntAA* (PA0195) and the lowest biofilm former missing *cbrB* (PA4726).

**mutant (PA2323; MPAO1_14370),** a gene whose product is involved in the synthesis and export of polysaccharides, was used as a reference point for low biofilm formation, while a *retS* mutant (PA4856; MPAO1_25880), encoding a pleiotropic regulator of multiple virulence factors, was used as a reference point for high biofilm formation. Overall, MPAO1 WT produced roughly twice the biofilm biomass of transposon mutants, suggesting that the transposon has an influence on biofilm formation and that it is more reliable to compare transposon mutants amongst each other. The transposon mutant PW7021 (an *arnB* mutant; PA3552; MPAO1_07345, see below) was chosen as an internal reference for biofilm formation as its biomass was found approximately midway through the 24 h biofilm readings in Fig. 4a. We confirmed that the *cbrB* mutant produced significantly less biofilm biomass (p value < 0.001) than the *arnB* mutant, similar to the low biofilm-forming *pslB* mutant. Biofilm growth of the *cbrB* mutant was also performed within the flow chamber to confirm the capacity of the device to assess differential biofilm formation. Similar to the 96-well plate screening assay, the *cbrB* mutant produced substantially less biofilm compared to the MPAO1 WT over 18 h in the flow chamber (Fig. 5c) and displayed a delayed exponential growth compared to WT and the other mutants tested (Supplementary Fig. 4). We also confirmed that the *pntAA* mutant produced higher biofilm biomass than other transposon mutants, similar to the high biofilm former *retS* mutant (Fig. 5a). However, compared to the WT, the *retS* mutant produced comparable biofilm biomass, which is likely caused by a decrease of strain fitness due to the transposon insertion. An alternative explanation is that the effect of *RetS* cannot be measured after 24 h because it has been shown previously that *RetS* turns non-functional in *P. aeruginosa* WT after 8 h following initial attachment. Genes identified by the proteomic analysis (vggG1b, cda, aprX; see “Result” section below) did not seem to affect the biofilm formation of MPAO1 in the conditions tested.

Next, we tested the strains for their biofilm resistance to colistin and included the *arnB* mutant strain PW7021 as a positive control (Supplementary Fig. 3). ArnB is a well-studied protein known to modify lipopolysaccharide (LPS) and have a key role in the resistance to colistin. The recovery of biofilm cells after treatment with 25 µg/mL colistin was compared to the recovery of non-treated biofilm cells (Fig. 4b) (see “Methods” section), as described previously. This concentration of colistin was much higher than the minimal inhibitory concentration (MIC) used for the planktonic *P. aeruginosa* MPAO1 (8 µg/mL) allowing us to focus specifically on biofilm cells. As expected, the *arnB* mutant exhibited a very low recovery after colistin treatment (97% less than the control without colistin) (Fig. 4b). In contrast, the *arnB* mutant produced robust biofilms in the biofilm screening assay (Fig. 4a), a phenotype that was confirmed using the microfluidic chamber (Fig. 4c). Notably, the *cbrB* mutant strain grown as a biofilm was also found to be sensitive to colistin (90% less recovery than the control without colistin; Fig. 4a), which might be
related to the low amount of biofilm produced by this mutant. In contrast, the high biofilm former pntAA mutant exhibited high resistance towards colistin with recovery close to the non-treated planktonic cells.

In a second step, the resistance profile of the identified mutants was characterized in more detail by measuring the MIC of planktonic cells and the minimal biofilm inhibitory concentration (MBIC) towards colistin (Fig. 5b). Two independent experiments (with four replicates in total) confirmed the significantly higher sensitivity of planktonic cells of

\[
\begin{array}{cccc}
\text{Gene inactivated} & \text{MIC of colistin (µg/mL)} & \text{MBIC 50 of colistin (µg/mL)} & \text{MBIC 90 of colistin (µg/mL)} \\
\text{None (WT)} & 8 & 50 & 200 \\
\text{arrB (PA3552)} & 2 & 8 & 12.5 \\
\text{cbrB (PA4726)} & 2 & 4 & 100 \\
\text{pntAA (PA0195)} & 16 & 200 & >200 \\
\text{vgrG1b (PA0095)} & 16 & 100 & >200 \\
\text{cdrA (PA4625)} & 8 & 50 & 200 \\
\text{aprX (PA1245)} & 16 & 100 & >200 \\
\end{array}
\]

Candidates selected from 1 screening and 2 proteomic analysis.

Protein abundance profiling of MPAO1 grown planktonically and in biofilms

To assess if we could identify proteins known to have a role in biofilm formation with the microfluidic chamber, we next generated shotgun proteomics data for MPAO1 cells grown to mid-exponential planktonic phase or as 72 h biofilms (3 replicates each). 1530 and 1728 proteins were identified in planktonic cells and biofilm, respectively, resulting in a combined 1922 of the 5799 annotated proteins (33.1%). Among the most significantly differentially abundant proteins (log2 fold change (FC) of ≥ 1 or ≤−1 and adjusted p value ≤ 0.05; see “Methods” section and Supplementary Fig. 5) several candidates were identified that have previously been linked with a role in biofilm formation. These included MuA (MPAO1_18330)\textsuperscript{46}, CbpD (MPAO1_21730)\textsuperscript{47}, AcnA (MPAO1_17965)\textsuperscript{48} and PilY1 (MPAO1_24155)\textsuperscript{49} (Fig. 6a, Table 3; see “Discussion” section). In addition, MPAO1_19625 was highly upregulated in biofilms (Fig. 6a). Notably, its PA01 homolog AprX was reported to be secreted by a type I secretion system\textsuperscript{45}, indicating that hypothetical proteins or proteins of unknown function can be linked to roles in biofilm formation and growth. We next looked for protein expression evidence for CDS missed in the fragmented short-read genome assemblies. We found that 21 of the 52 CDS missed in the MPAO1/P1 assembly were detected at
the protein level (Supplementary Data 1). Notably, this included two proteins significantly upregulated in the biofilm, namely MPAO1_00520 (T6SS tip protein VgrG1b) located close to the H1-T6SS cluster \cite{44} and MPAO1_24535 (Fig. 6a), the homolog of PAO1 CdrA, a cyclic-di-GMP-regulated adhesin known to reinforce the biofilm matrix \cite{50}, again underlining the importance of a complete genome sequence for downstream functional genomics analyses. Notably, nine of 14 structural genes of H1-T6SS, one of overall three T6SSs in \textit{P. aeruginosa} that helps it to prevail under stressful conditions \cite{51}, were upregulated around two-fold or more in biofilm (Supplementary Fig. 6). Similarly, all three VgrG1 proteins (1a-1c) that are co-regulated with the H1-T665 \cite{52} were upregulated in biofilm, while none of the other seven VgrG family members were expressed. Among the proteins downregulated in 72 h biofilms, three are associated with the iron acquisition; isochorismate synthase (MPAO1_03800), a rate-limiting enzyme involved in the production of salicylate (precursor of the siderophore pyochelin) \cite{53}, the siderophore receptor MPAO1_23930 (PuiA), and the siderophore-interacting protein MPAO1_15475. Iron acquisition is deemed necessary for \textit{P. aeruginosa} biofilm formation \cite{54} so their
Table 3. List of 61 proteins with significant differential abundance (see text) or unique expression when comparing biofilm grown and planktonic cells.

| Locus tag          | Gene     | Product                                                                 | log2 FC | p_adj | Comment, reference |
|--------------------|----------|-------------------------------------------------------------------------|---------|-------|--------------------|
| **Biofilm only**   |          |                                                                        |         |       |                    |
| MPAO1_19985        | napA     | Nitrate reductase catalytic subunit NapA                               | 5.02    | 0.05  |                    |
| MPAO1_04195        | SH3       | Domain-containing protein                                               | 5.02    | 0.05  |                    |
| MPAO1_10705        | Methyl-accepting chemotaxis protein                                    | 5.11    | 0.03  |        |
| MPAO1_17160        | EscC/YscC/HrcC family-type III secretion system outer membrane ring protein | 5.11    | 0.03  |        |
| MPAO1_21585        | Itaconyl-CoA hydratase                                                 | 5.19    | 0.04  |        |
| MPAO1_17195        | Translocator outer membrane protein PopD                               | 5.19    | 0.02  |        |
| MPAO1_17200        | Hypothetical protein                                                   | 5.34    | 0.01  |        |
| **MPAO1_00520**    | vgrG1b*  | **Type VI secretion system tip protein VgrG1b**                        | 5.41    | 0.01  | H1-T6SS^44         |
| MPAO1_20935        | Beta-keto-ACP synthase                                                 | 5.61    | 0.04  |        |
| MPAO1_24325        | Cytochrome c551 oxidoreductase                                          | 6.11    | 0.00  |        |
| **Diff. Abundant** |          |                                                                        |         |       |                    |
| MPAO1_07815        | Osmoprotectant NAGGN system M42 family peptidase                       | 4.70    | 0.02  |        |
| MPAO1_19625        | aprX     | Hypothetical protein                                                   | 5.45    | 0.00  | 45                |
| MPAO1_24535        | cdrA*    | Filamentous hemagglutinin N-terminal domain-containing protein          | 6.54    | 0.00  | 50                |
| MPAO1_02725        | nirF     | Protein NirF                                                           | 4.30    | 0.01  |                    |
| MPAO1_24530        | cdrB*    | ShlB/FhaC/HecB family hemolysin secretion/activation protein            | 4.35    | 0.01  | 50                |
| MPAO1_25250        | BON domain-containing protein                                          | 3.28    | 0.05  |        |
| MPAO1_19595        | Serralysin                                                                     | 3.75    | 0.01  |        |
| MPAO1_22090        | putA     | Bifunctional proline dehydrogenase/L-glutamate gamma-semialdehyde dehydrogenase PutA | 3.00    | 0.01  |        |
| MPAO1_18330        | muiA*    | Mucoidy inhibitor MuiA                                                  | 2.69    | 0.01  | 46                |
| MPAO1_21730        | cbpD*    | Chitin-binding protein                                                  | 2.79    | 0.00  | 47                |
| MPAO1_06120        | Copper chaperone Pc(Ac)                                               | 1.98    | 0.03  |        |
| MPAO1_14990        | NAD(P)-dependent alcohol dehydrogenase                                 | 2.22    | 0.01  |        |
| MPAO1_02740        | nirS     | Nitrite reductase                                                       | 2.52    | 0.00  |        |
| MPAO1_25230        | DUF748 domain-containing protein                                       | 1.85    | 0.02  |        |
| MPAO1_18000        | ccoP     | Cytochrome-c oxidase, cbb3-type subunit III                            | 1.60    | 0.05  |        |
| MPAO1_28880        | adhP     | Alcohol dehydrogenase AdhP                                             | 2.52    | 0.00  |        |
| MPAO1_07010        | Phosphoketolase                                                        | 2.07    | 0.00  |        |
| MPAO1_00100        | LysM peptidoglycan-binding domain-containing protein                   | 1.44    | 0.03  |        |
| MPAO1_02290        | TonB-dependent receptor                                                | 1.66    | 0.01  |        |
| MPAO1_27435        | Amino acid ABC transporter substrate-binding protein                   | –3.09   | 0.03  |        |
| MPAO1_05385        | DUF1302 domain-containing protein                                      | –2.80   | 0.03  |        |
| MPAO1_17965        | acnA*    | Aconitate hydratase                                                    | 1.49    | 0.01  | 48                |
| MPAO1_24155        | pilY1*   | Type 4a pilus biogenesis protein PilY1                                  | 1.54    | 0.01  | 49                |
| MPAO1_05375        | Fatty acid–CoA ligase                                                 | –5.06   | 0.01  |        |
| MPAO1_04650        | OmpW family protein                                                   | 1.49    | 0.01  |        |
| MPAO1_00495        | tssH     | Type VI secretion system ATPase TssH                                   | 1.27    | 0.03  | H1-T6SS^44         |
| MPAO1_14010        | Non-ribosomal peptide synthetase (NRPS)                                | 1.90    | 0.02  |        |
| MPAO1_26210        | azu      | Azurin                                                                 | 2.45    | 0      |        |
| MPAO1_13620        | Xanthine dehydrogenase family protein molybdopterin-binding subunit   | –4.33   | 0.01  |        |
| MPAO1_03800        | pchA     | Salicylate biosynthesis isochorismate synthase                         | –3.04   | 0.01  |        |
| MPAO1_06095        | TonB-dependent copper receptor                                         | 1.74    | 0.00  |        |
| MPAO1_03775        | Catalase                                                              | 1.67    | 0.00  |        |
| MPAO1_02430        | clpG     | AAA family protein disaggregate ClpG                                    | 2.31    | 0.00  |        |
| MPAO1_26945        | Poly(3-hydroxyalkanoate) granule-associated protein PhaF               | 1.22    | 0.03  |        |
| MPAO1_23990        | Prepilin-type cleavage/methylation domain-containing protein           | 3.01    | 0.00  |        |
| MPAO1_02180        | Response regulator                                                    | 1.13    | 0.00  |        |
| MPAO1_05390        | DUF1329 domain-containing protein                                      | –2.62   | 0.00  |        |
| MPAO1_13900        | NADP-dependent glyceraldehyde-3-phosphate dehydrogenase               | –1.11   | 0.05  |        |
down-regulation was unexpected, however, this response is likely circumvented by the utilization of alternative iron acquisition strategies including the high-affinity siderophore pyoverdine.

Finally, to identify unannotated short ORFs that may carry out important functions or new start sites, we created an integrated proteogenomics search database (iPtgxDB) for strain MPAO1 and PAO1 (Supplementary Table 6), which cover their entire coding potential. As search combined with stringent result filtering (see “Methods” section) allowed us to identify unambiguous peptide evidence for a 44 aa longer proteoform of MPAO1_08365 (predicted by Prodigal, an ab initio gene prediction algorithm; Fig. 6b). In addition, we obtained proteogenomic evidence supporting a single nucleotide insertion in MPAO1_25975 in strain MPAO1 as compared to PA4875 (annotated as pseudogene) in strain PAO1 (Fig. 6c). The peptide that supported this single nucleotide change at the amino acid level was identified with seven peptide spectrum matches (PSMs), illustrating the ability to identify SNP changes at the protein level, with implications for clinical proteomics.

**DISCUSSION**

*P. aeruginosa* is a member of the ESKAPE pathogens, the lead cause of worldwide nosocomial infections. Along with many other clinically relevant bacteria, it can form biofilms whose emergent properties include a much higher tolerance to antimicrobials. Together with the increased mutation rates in biofilm compared to planktonic cells, this further complicates treatment and cure of biofilm-based infections. The development of model systems allowing the study of antimicrobial tolerance mechanisms and the evolutionary dynamics that lead to AMR development in biofilms is thus of utmost priority.

We here developed and validated such a model system for *P. aeruginosa* MPAO1 (Fig. 7). Conceptually, the model was designed to integrate genotype data with phenotypic information and to leverage the wealth of existing public genetic resources and functional genomics data sets. A complete, fully resolved genome sequence is one critical element, which recently allowed linking of genotypic differences of nine Pseudomonas plant microbiome isolates with their varying biocontrol potential.

While a complete genome existed for *P. aeruginosa* PAO1, only three fragmented Illumina-based genome assemblies were available for MPAO1, the parental strain of the popular UW transposon mutant library. These included strains MPAO1/P1 and the recently sequenced PAO1-2017-E and PAO1-2017-I. On average, they lacked between 55 to 66 genes (40–52 CDS) compared to our complete MPAO1 genome (Supplementary Data 1). For MPAO1/P1, these included the essential *ftsY*, an adhesin, several T6SS effectors (see below), and four of the overall eight NRPSs. NRPSs are highly relevant for AMR as they often represent enzymes involved in the biosynthesis of antibiotics. In fact, due to the multi-resistant phenotype of ESKAPE pathogens, concerted efforts aim to describe their NRPS gene clusters in search of new therapeutic approaches, reinforcing the need for complete genome sequences.

Comparative genomics with the PAO1 type strain uncovered an inventory of conserved and strain-specific genes, and a list of genome-wide SNPs, extending an earlier study that had compared a subset of genomic regions. Among the 232 MPAO1-unique gene clusters, bacteriocins were enriched, which have a role in restricting the growth of closely related microbial competitors to gain an advantage in colonizing a variety of environments. The complete MPAO1 genome enabled us to remap valuable existing Tn-seq data sets from relevant conditions, thereby identifying 39 MPAO1-unique essential genes that had escaped detection so far. The complete MPAO1 genome enabled us to remap valuable existing Tn-seq data sets from relevant conditions, thereby identifying 39 MPAO1-unique essential genes that had escaped detection so far due to reference-based PAO1 mapping. 18 of these genes were essential in at least 50% of the 16 Tn-seq samples, and six represented general essential genes, including a Phd/YefM family type antitoxin (*MPAO1_22380*), which was essential in all samples. This is worth noting given the relevance of toxin-antitoxin systems for bacterial growth arrest and persistence. Importantly, our data do not conflict with results from previous studies; rather, they open the field to study the roles of additional MPAO1-unique essential genes. Furthermore, our results suggest that groups planning to construct inventories of core essential genes in other pathogens, following the elegant approach of Poulsen et al. who had considered both relevant media mimicking different infection types and nine strains from different lineages of a *P. aeruginosa* phylogenetic tree, should ideally select complete genomes without any genomic blind spots.

To leverage the experimental arm of our model (Fig. 7), the consortium developed a PDMS microfluidic flow chamber for...
biofilm growth, which offers several significant advantages. It provides laminar flow conditions inside the channels (Supplementary Table 4), allows gas exchange, decreases the amount of growth medium, facilitates heat transfer, is inexpensive to replicate, and permits imaging of the biofilm and easy harvesting for biochemical characterization. While the flow chamber can be used to monitor biofilm formation on both glass (oxygen impermeable) and PDMS, it is more relevant to investigate biofilm formation on PDMS as a widely applied biomaterial used in indwelling devices and implants. We observed that biofilms on PDMS formed a more homogeneous layer (Fig. 3b) as compared to the commonly observed mushroom-like structures of P. aeruginosa biofilms on glass. This effect is not related to hydrodynamics as a flow chamber that previously has been shown to produce mushroom-like structures has hydrodynamics ($\bar{u} \approx 208 \text{ µm/s}$ and $Re = 0.24$) comparable to our microfluidic chip. We speculate that the effect is most likely explained by two differences: (i) PDMS is oxygen permeable and can transport oxygen to the base of the biofilm that then manifests in overall biofilm biomass and exopolysaccharides (EPS), inactivation studies showed that the gene $cbrB$ is defective in both the microtiter plate and flow chamber. In addition, inactivating $cbrB$ was found to be as inhibitory for biofilm formation as inactivating the gene $psIB$, known to negatively influence biofilm matrix synthesis. As part of the two-component system $CbrAB$, a mutation in the response regulator $cbrB$ is known to negatively affect the use of several carbon and nitrogen sources. Such a defect could explain the low growth rate, the low biofilm biomass and therefore the low resistance to colistin of this mutant. Using P. aeruginosa PA14, it was shown that a mutation in $CbrA$ improved biofilm formation, while a mutation in $CbrB$ did not. However, these differences might be explained by strains (MPAO1 versus PA14) or growth media used (M9 versus BM2-biofilm medium). In contrast, our screening revealed that inactivating the transhydrogenase $pntAA$ induced high biofilm formation, comparable to the known gene $rets$. While redox balance is known to correlate with biofilm morphology, the precise role of $pntAA$ remains to be investigated. Together, the combined data of the screen and flow chamber experiments demonstrated that genes previously not implicated in AMR and biofilm formation can be identified and that the function of known genes can be validated.

The differential proteomics data confirmed proteins known to have a role in biofilm formation and growth. These included $MuiA$, which inhibited swarming motility and enhanced biofilm formation (roles, that were validated in knockout strains) and $CbpD$, for which higher protein abundance had been observed in late phases of biofilm growth; accordingly, mutants displayed a lower amount of biofilm growth and exopolysaccharides (EPS). Similarly, for two other proteins with significantly higher abundance in biofilms, inactivation studies showed that the gene...
encoding AcnA impaired biofilm formation and was required for microcolony formation\(^3\), while an increased abundance of PIY1 repressed swarming and increased biofilm formation, as confirmed by knockout experiments\(^4\). Biofilm exclusive protein expression was observed for MPAO1_00520, the T6SS VgrG1b effector protein\(^5\), while the adhesin CdrA (MPAO1_24535)\(^6\) was highly upregulated in biofilms. Both genes were missed in the MPAO1/P1 genome. CdrA forms a two-partner secretion system with CdrB, and both were upregulated under elevated c-di-GMP levels\(^7\), in line with the upregulation we observed in biofilm. Moreover, an NRRS (MPAO1_14010) and the hypothetical protein MPAO1_19625 were significantly upregulated in biofilm (Table 3). The data provided insights beyond the top differentially abundant proteins. Notable examples included immunity protein TplE\(^8\) (PAI1509, MPAO1_18250), a bacteriocin of the H2-T6SS\(^9\), which was exclusively expressed in biofilm (Supplementary Data 1), and upregulation of nine of 14 structural members of H1-T6SS\(^10\) (Supplementary Fig. 6). Active T6SSs have been associated with chronic infections in cystic fibrosis patients\(^11\), and H1-T6SS has an important role in the dominance of \(P.\) \(aeruginosa\) in multi-species biofilms\(^12\). More sensitive and comprehensive proteomics studies are needed to overcome the limitation that only a third of the theoretical proteome was identified with our shotgun proteomics approach, e.g., by combining data-dependent and data-independent acquisition and the use of spectral libraries\(^13\), allowing a more comprehensive identification of lower abundant and small proteins, or by analyzing additional conditions or mutant strains under which tightly regulated proteins such as the Tse toxins (secreted substrates of the H1-T6SS) are expressed (Supplementary Fig. 6)\(^14\).

The public MPAO1 (and PAO1) iPtxgDBs allows the identification of missed genes by proteogenomics\(^15\), which often encode short proteins (sProteins) that can carry out important functions\(^16,17\). Interestingly, Tn-seq data from the Manoil group had implied an essential genomic region in the PF1 phage region of PAO1-UW\(^18\). Re-mapping their data, we identified a general essential gene (MPAO1_22380) annotated in our MPAO1 genome whose homolog had been missed in the PAO1 genome annotation, and which appeared to encode the antitoxin member of a ParDE-like TA system (PAO7281, Fig. 2). However, we did not identify expression evidence for the antitoxin MPAO1_22380 (83 aa) with our iPtxgDB, most likely because our data set (33% of MPAO1 proteins) was not as extensive as that used in a comprehensive proteogenomic study (85% of \(Bartonella henselae\) proteins\(^19\), whose complete membrane proteome coverage included expression evidence for all T4SS members\(^20\). Nevertheless, we observed proteogenomic evidence for gene products missed in the fragmented MPAO1/P1 genome, for new start sites, and for single amino acid variations, underlining the potential value of proteogenomics for application in clinical proteomics.

Our proof of principle experiments uncovered several candidates for follow-up studies and illustrated the benefit of the complete MPAO1 genome, which led to the discovery of six general essential genes not contained in the transposon library, and which will allow identifying evolutionary changes that lead to AMR in biofilm by deep sequencing in the future. Having been validated for the generation of reproducible inter-laboratory \(P.\) \(aeruginosa\) biofilm results, a milestone to recover the potential value of proteogenomics for application in clinical proteomics.

As a proof of principle, we have developed several approaches to study phenomena related to biofilm-associated AMR.

**METHODS**

**Bacterial growth and genomic DNA extraction**

\(P.\) \(aeruginosa\) strain MPAO1 (originating from the lab of Dr. Barbara Iglewski) was obtained from Prof. Colin Manoil, UW (Seattle, USA) together with the transposon insertion mutant collection of ~5000 mutated genes (4937 strains)\(^21\). For DNA extraction, the MPAO1 cytoculture was streaked out on 20% BHI solid medium (7.4 g in 1 L water) containing 1.5% agar (both Sigma, Switzerland). Shaken 20% BHI fluid cultures were inoculated from a single colony and grown at 30 °C until the mid-exponential phase (OD600 = 0.5). Genomic DNA (gDNA) was extracted with the GeneElute kit (Sigma, Switzerland), following the Gram-negative protocol, including RNase treatment. A study that had analyzed 9331 complete bacterial genomes\(^22\) (NCBI RefSeq, assembly category: ‘complete genome’, status Feb. 23, 2018; see their TableS4) reported that 106. \(P.\) \(aeruginosa\) strains have been sequenced completely, which included only two PAO1 strains (and no complete genome of strain MPAO1). 38/106 (36%) had difficulty assembling genomes with repeat pairs >10 kilo base pairs (bp).

**Sequencing, de novo genome assembly, and annotation**

PacBio SMRT sequencing was carried out on an RS II machine (1 SMRT cell, P6-C4 chemistry). A size selection step (BluePippin) was used to enrich for fragments longer than 10 kb. The PacBio run yielded 105,221 subreads (132 Gbp sequence data). Subreads were de novo assembled using the SMRT Analysis portal v5.1.0 and HGAP\(^4\), and polished with Arrow. In addition, a 2 x 300 bp paired-end library (Illumina Nextera XT DNA kit) was sequenced on a MiSeq. Polishing of the assembly with Illumina reads, circularization, start alignment using dnaA, and final verification of assembly completeness was performed as described previously\(^23\). The quality of the aligned reads and the final chromosome was assessed using Qualimap\(^24\). In addition, we checked for any potential large scale mis-annotations using Sniffles v1.0.8\(^25\) by mapping the PacBio subreads against the Genome Annotation Pipeline (v0.2.6\(^26\) and SPAdes v3.7.1\(^27\) were run on the Illumina data to detect smaller plasmids that might have been lost in the size selection step. The genome was annotated with the NCBI’s prokaryotic genome annotation pipeline (v3.3)\(^28\). Prophages were identified with Phaster\(^29\). Detailed annotations for all CDS were computed as described previously\(^3\); this included assignment to Cluster of Orthologous Groups (COG) categories using eggnog-mapper (v1.0.3) and EggNOG 4.5, an Interproscan analysis and prediction or /integration of subcellular localizations, lipoproteins, transmembrane helices and signal peptides (for details, see Supplementary Data 1).

**Comparative genomics of selected PAO1 genomes**

The genome of the \(P.\) \(aeruginosa\) PAO1-UW reference strain\(^2\) was compared to our complete MPAO1 genome using the software Roary\(^3\) to define core and strain-specific gene clusters as described before\(^30\). A BlastP analysis helped to correctly identify conserved genes with ribosomal slippage (prfB; peptide chain release factor B) or that encodes selenocysteine (MPAO1_25645), which otherwise can be misclassified as unique gene; genes of 120 bp or below (17 in MPAO1) were not considered. ProgressiveMauve\(^31\) was used to align the genomes globally and to identify larger genomic differences. Small differences (indels, single nucleotide polymorphisms (SNPs)), were identified against the PAO1 reference strain as described previously\(^32\). Alternatively, contigs from the MPAO1/P1 genome\(^33\) were aligned to our complete MPAO1 genome assembly using BWA mem\(^34\). Bedtools v2.16.1 “gencov\(^35\)” was used to calculate a gene-wise coverage, allowing to identify genes that were missed in the 140 contigs.

Re-mapping of Transposon-sequencing data

MPAO1 Tn-seq data sets\(^24\) were downloaded from NCBI’s SRA (SRP052838) and mapped back to both the PAO1-UW reference strain genome\(^2\) and our MPAO1 assembly following the scripts and notes provided in the Supplement. Insertion sites were computed as described by the authors, random mapping to multiple genome positions were assigned randomly, and the number of insertion sites per gene was used to differentiate essential and non-essential genes as described\(^24\). Genes with zero insertions were considered essential; for the remaining genes, normalized read counts
across all insertion sites per gene (considering insertions falling within 5–90% of the length of each gene) were log2 transformed and fitted to a normal distribution. Genes with a p value < 0.001 were added to the list of essential genes. Finally, essential and conditionally essential genes were identified among the three main growth conditions (LB medium, minimal medium, sputum) as described\(^\text{15}\). Data from each growth condition consisted of multiple mutant pools for LB, two mutant pools for LB-1 and three mutant pools for LB-2 (LB-1: 3 replicates; LB-2: 2 replicates). For LB, genes were considered essential in the mutant pool LB-1 and LB-2 if at least two of three (LB-1) and one of two replicates (LB-2) agreed. Next, a consensus set of essential genes in LB and the minimal medium was derived from those genes that were essential in at least two of three mutant pools (LB-1, LB-2, and LB-3) in LB and minimally respectively. Similarly, essential genes in sputum (four mutant pools) were derivated if data from at least three of four pools agreed. Finally, genes that were essential in all three growth conditions were called "general essential genes (312)" and genes essential to a specific growth condition were called "condition-specific essential genes". Together, they comprise "all essential genes (577)"; for further details, see Supplement.

Microfluidic chamber used for biofilm growth

The standardized microfluidic flow chamber consisted of a PDMS chip with a straight microfluidic channel (30 mm length × 2 mm width × 0.200 mm depth) that naturally adhered to a glass coverslip (26 × 60 mm; thickness no.1). The microfluidic chamber was fabricated using SU-8 spin-coated to a thickness of 200 μm on a silicon wafer in advance of standard soft lithography replication into PDMS [84]. From this, polyurethane clones of the structures were prepared to upscale production and for sharing microfluidic molds between laboratories. A degassed 10:1 mixture of Sylgard 184 PDMS base and curing agent was cured in an oven at 60 °C for 2 h. Following cooling and retrieval from the SU-8 wafer the structured PDMS was attached, structures facing upwards, to a silicone baking mold using a transparent double-sided adhesive (3M). The PDMS part was degassed, while the two-component polyurethane (Smooth-Cast™ 310) solutions were each thoroughly shaken for 10 min and then combined in a 1:1 ratio followed by thorough mixing (by repeat inversion and then shaking). The PDMS device was then submerged in the mixture, with degassing for 10 min, after which the mold was left overnight in a well-ventilated area followed by a hard bake at 60 °C for 4 h. Once cooled the PDMS device was retrieved leaving the polyurethane mold in readiness for replica molding fresh PDMS devices again at 60 °C for 2 h. Importantly, PDMS devices are only retrieved after the polyurethane mold has cooled to room temperature to allow the repeated replication (>100 times) of precision PDMS microfluidic chambers. Inlet and outlet ports were prepared 1 mm diameter biopores, while biofilm formation was achieved by filtering 70% ethanol for 15 min at a rate of 20 μL/min, before rinsing with sterile PBS for 15 min and then flushing with M9 minimal medium (Formedium Ltd, Hunstanton, England) for another 15 min at the same flow rate.

Device inoculation, biofilm staining, and confocal laser microscopy

P. aeruginosa MPA01 was inoculated with 500 μL of an M9-grown overnight pre-culture and grown for ~16–18 h in 10 mL M9 medium (1x M9 salts supplemented with 2 mM MgSO\(_4\), 100 μM CaCl\(_2\), and 5 mM glucose) at 37 °C with gentle rotation (150 rpm) until a cell concentration of 1.3 × 10\(^8\) bacteria/mL was reached. One mL of the culture was then washed twice with PBS (pH 7.0) by centrifugation at 5000xg for 5 min at 10 °C. The bacterial pellet was resuspended and diluted in PBS + 2% S9 detergent (prepared in demineralized water), rinsed with tap water, then immersed in 96% ethanol and sonicated for 5 min, followed by a final rinse with demineralized water and then autoclaved. The inlet and outlet of the microfluidic flow chamber were connected to a syringe pump with a 25 G needle and waste container, respectively, via sterile PTFE tubing (Smiths Medical, ID: 0.38 mm, OD: 1.09 mm). The chamber was disinfected by flowing 70% ethanol for 15 min at a rate of 20 μL/min, before rinsing with sterile PBS for 15 min and then flushing with M9 minimal medium (Formedium Ltd, Hunstanton, England) for another 15 min at the same flow rate.

1 mL of sterile demineralized water) through the flow chamber at at 5 μL/min. Once the channel was filled, the flow was stopped and the biofilm kept in the dark for 30 min to allow dye penetration. Finally, PBS was blown through the system at 5 μL/min for 30 min to remove the staining agent. Confocal imaging was performed using a Leica SP8 with x63 oil immersion lens (HC PL APO CS2 ×63/1.30, Southampton; LabA), a Leica SP8 with x63 water immersion lens (HC PL APO ×63/1.20 W CORR CS2; BAM, LabB), and a Leica SP2 with x62 water lens (HCX APO L ×63/0.90 W; Groningen, LabC) for 3 biological repeats comprising 3 technical repeats per site (n = 9 biological/n = 27 technical). Z-stacks (1 μm) were taken of the biofilms formed on the PDMS surface of the device at five separate regions (besides the inlet, 25%, 50%, 75%, and beside the outlet). COMSTAT 2.1 (Image J) analysis of combined confocal data was performed to provide a quantification of average thickness and Live/Dead biovolume\(^\text{16}\). A 2-way ANOVA multiple comparisons was performed with Tukey’s post hoc test to determine 95% confidence intervals. Similar conditions were applied to strain PA4726 (cb8) that had shown reduced biofilm growth during screening, and PA3552 (arnB) which demonstrated robust biofilm formation. Biofilm formation of both mutant strains was compared to the MPA01 WT strain after 18 h growth in the flow chamber.

Screening the public MPA01 transposon library for antibiotic resistance

The protocol to assess the antibiotic resistance of biofilm-forming MPA01 was adapted from a previous study\(^\text{20}\). Frozen gene banks of 95 randomly selected mutants of the UW Genome Center’s P. aeruginosa PAO1 transposon mutant library\(^\text{13}\), each harboring a transposon insertion inactivating the function of the respective gene, were allowed to recover in 20% BHI overnight at 150 rpm and 37 °C. All subsequent incubations were done at 37 °C in 96-well plates (TPP tissue culture 96-well plates, 2707902, Sigma-Aldrich) covered with an air-permeable foil (Breathe-Easy sealing membrane, Z380059, Sigma-Aldrich) without further shaking. The overnight cultures were diluted 10 fold in M9 medium and 100 μL each was distributed in six plates (1 well/mutant/plate). After 24 h incubation, the biofilm formation from two plates was quantified by crystal violet staining, while biofilms from the other four plates were washed with 0.9% NaCl to remove planktonic bacteria. Bacteria were then exposed to either M9 or M9 supplemented with 25 μg/mL of colistin, i.e., much higher than the minimal inhibitory concentration (MIC) for the planktonic growth of P. aeruginosa (4 μg/mL), allowing us to focus specifically on the biofilm bacteria. After 24 h treatment, the medium was removed, biofilms were washed with 0.9% NaCl to remove all traces of antibiotics, and bacteria were allowed to recover in fresh colistin-free M9 medium. After 24 h incubation, the recovery of biofilm bacteria was measured by turbidity (OD\(_{550}\)) to reveal if the mutation influenced the biofilm resistance attributed by the biofilm. To confirm the reliability of our screening, promising mutants were analyzed independently in triplicate. Cell suspensions of each mutant were prepared in M9 medium (5 × 10\(^4\) CFU/mL) and biofilm biomass was quantified by crystal violet after 24 h incubation at 37 °C. Biofilm cell resistance was quantified by measuring the turbidity of biofilm suspension after 24 h treatment with different concentrations of colistin and after 24 h recovery in fresh M9 medium. Selected mutants of interest were further characterized to assess biofilm formation (as described above), MIC, and MBIC (see Supplementary Fig. 3 for detail).

Protein extraction from MPA01 planktonic and biofilm cultures

For planktonic protein extractions, 10 mL MPA01 was grown overnight (~18 h) in M9 medium under gentle rotation (150 rpm), centrifuged at 4000xg/5 min/RT, and the pellet resuspended in 1 mL Hanks’ Balanced Salt Solution (HBSS). Biofilms were grown for 72 h using the microfluidic device as previously described, the PDMS device removed from the glass coverslip, and the combined biofilm biomass from 3 lanes harvested into 1 mL HBSS. Cells from both populations were washed twice in HBSS at 10,000xg/5 min/RT and the pellets resuspended in 1 mL lysis buffer (7 M urea, 2 M thiourea, 35 mM CHAPS, 20 mM DTT, 1 M NaCl). Samples were frozen at −80 °C for 30 min and then thawed at 34 °C for 20 min. Trichloroacetic acid (TCA) precipitation was performed by adding the bacterial samples to 100% ice-cold acetone and 100% trichloroacetic acid in a 1:1:1 ratio and precipitating at −20 °C for 1 h. Samples were then centrifuged (18,000xg/10 min/4 °C), the supernatant discarded, and the pellet washed twice with 1 mL ice-cold acetone (18,000 x g/10 min/4 °C). Acetone was removed, the pellet air-dried at room temperature, and resuspended in 0.1 M Triethylenediammonium bicarbonate (TEAB) plus 0.1%
Rapigest. Protein sample validation was performed by 1DE gel electrophoresis. 19.5 μL sample was added to 7.5 μL NuPAGE LDS buffer and 3 μL NuPAGE reducing reagent, heated at 70°C for 10 min, then run on a NuPAGE 4–12% Bis-Tris gel with MOPS buffer at 200 V for 50 min alongside a Novex Sharp standard. The gel was stained with SimplyBlue Safe Stain for 1 h, then destained with dH2O.

Protein processing, mass spectrometry, and database search
Protein samples were heated at 80 °C for 10 min, then DTT added at a final concentration of 2 mM and incubated at 60 °C for 45 min. Samples were then briefly vortexed, pulse spun, and cooled to room temperature before adding iodoacetamide to a final concentration of 6 mM. Samples were incubated at room temperature for 45 min (protected from light), vortexed and pulse spun briefly, then trypsin added at a final concentration of 1.3 μg/mL. Following incubation overnight at 37 °C (protected from light), trzylofluorocytic acid (TFA) was added to a final concentration of 0.5% then incubated at 37 °C for 30 min. Samples were centrifuged at 13,000g for 10 min at RT, the supernatants removed and vacuum concentrated. The resultant pellets were resuspended in 3% acetonitrile + 0.1% trzylofluorocytic acid and peptide quantification performed using the Direct Detect system (Merck Millipore). Protein samples were normalized then vacuum concentrated in preparation for mass spectrometry.

Peptide extracts (1 μg on column) were separated on an Ultimate 3000 RSLC nano system (ThermoScientific) using a PepMap C18 EASY-Spray LC column, 2 μm particle size, 75 μm x 75 cm column (ThermoScientific) over a 140 min (single run) linear gradient of 3–25% buffer B (0.1% formic acid in acetonitrile (v/v)) in buffer A (0.1% formic acid in water (v/v)) at a flow rate of 300 nL/min. Peptides were introduced using an EASY-Spray source at 2000 V to a Fusion Tribrid Orbitrap mass spectrometer (ThermoScientific). The ion transfer tube temperature was set to 275 °C. Full MS spectra were recorded from 300 to 1500 m/z in the Orbitrap at 120,000 resolution using TopSpeed mode at a cycle time of 3 s. Peptide ions were isolated using an isolation width of 1.6 amu and trapped at a maximal injection time of 120 ms with an AGC target of 300,000. Higher-energy collisional dissociation (HCD) fragmentation was induced at an energy setting of 28 for peptides with a charge state of 2–4. Fragments were analyzed in the Orbitrap at 30,000 resolution. Analysis of raw data was performed using Proteome Discoverer software (ThermoScientific) and the data processed to generate reduced charge state and deisotoped precursor and associated product ion peak lists. These peak lists were searched against the P. aeruginosa MPA01 protein database (a max. of one missed cleavage was allowed for tryptic digestion, the variable modifications were set to contain oxidation of methionine and N-terminal protein acetylation, and carboxyamidomethylation of cysteine was set as a fixed modification). The FDR was estimated with randomized decoy database searches and was filtered to below 1% FDR at the protein level. Differentially abundant proteins were identified using DESeq2, significantly differentially abundant proteins had an adjusted (multiple testing corrected) p value ≤ 0.05 and a log 2 fold change of ≥ 1 or ≤ –1.

Proteogenomics
An iPTgxDB was created for P. aeruginosa MPA01 as described previously15, using the NCBI annotation as anchor annotation. Ab initio gene predictions from Prodigal14 and ChemGenome16 and a modified in silico prediction that considers alternative start codons (TTG, GTG, CTG) and ORFs above 6 amino acids (aa) in length were integrated into a step-wise fashion. Proteomics data from MPA01 cells grown planktonically or as biofilm were searched against this iPTgxDB with MS-GF+ (v2019.04.18)92 using Cysteine carbamidomethylation as fixed, and oxidation of methionine as variable modifications. Using the target-decoy approach of MS-GF+, the FDR at the PSM level was estimated and filtered below 0.2%. Only unambiguous peptides as identified by a PeptideClassifier analysis16, using the extension that supports proteogenomics for prokaryotes15, were considered.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
The MPA01 genome sequence is available at NCBI Genbank (acc# CP027857; Bioproject: PRJNA438597, Biosample: SAMN08722738). Read data are available under SRR10153205 (Illumina) and SRR10153206 (PacBio). Proteomics data are available from PRIDE (acct# PXD017122) upon acceptance of the manuscript. The iPtgxDBs for P. aeruginosa MPA01 and PA01 are available from https://iptgxdb.expasy.org, both as a searchable protein database (FASTA format) and a GFF file, which can be loaded in a genome viewer and overlaid with experimental evidence. Biofilm growth data from the microfluidic chamber will be made available at https://doi.org/10.21235/DMMJ.c.4851463. To support technology dissemination, the polyurethane master molds of the microfluidic chambers are available upon request from the UoSNBIC; a CAD file can be found as Supplementary Data 5. Code availability: all analyses presented rely on open source software or published code that is referenced.

CODE AVAILABILITY
Open-source R code used for genomic, Tx-seq, and proteomics data processing is available from the authors upon request.

Received: 11 February 2020; Accepted: 7 October 2020; Published online: 30 October 2020

REFERENCES
1. Moradali, M. F., Ghods, S. & Rehm, B. H. Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front. Cell Infect. Microbiol. 7, 39 (2019).
2. Strier, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406, 959–964 (2000).
3. Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322 (1999).
4. Mah, T. F. & O’Toole, G. A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34–39 (2001).
5. Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34, 634–640 (2002).
6. Partridge, S. R., Kwong, S. M., Firth, N. & Jensen, S. O. Mobile genetic elements associated with antimicrobial resistance. Clin. Microbiol. Rev. 31, e0088-00017 (2018).
7. Lister, P. D., Wolter, D. J. & Hanson, N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22, 582–610 (2009).
8. Fernandez, L. & Hancock, R. E. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin. Microbiol. Rev. 25, 661–681 (2012).
9. Li, X. Z., Plesiat, P. & Nikaio, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
10. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009).
11. Rice, L. B. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol. 31(Suppl 1), 57–510 (2010).
12. Donlan, R. M. & Costerton, J. W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167–193 (2002).
13. Hall, C. W. & Mah, T. F. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol. Rev. 41, 276–301 (2017).
14. Mulcahy, L. R., Burns, J. L., Lory, S. & Lewis, K, E. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J. Bacteriol. 192, 6191–6199 (2010).
15. Crabbe, A., Jensen, P. O., Bjomsholt, T. & Coeyne, T. Antimicrobial tolerance and metabolic adaptations in microbial biofilms. Trends Microbiol. 27, 850–863 (2019).
16. Colpken, M. & Jewish Langensensino anoxic Pseudomonas aeruginosa biofilm to ciprofloxacin. Antimicrob. Agents Chemother. 61, e01024–01017 (2017).
17. Conibear, T. C., Collins, S. L. & Webb, J. S. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS ONE 4, e6289 (2009).
18. McElroy, K. E. et al. Strain-specific parallel evolution drives short-term diversification during Pseudomonas aeruginosa biofilm formation. Proc. Natl Acad. Sci. USA 111, E1419–E1427 (2014).
19. Chandler, C. E. et al. Genomic and phenotypic diversity among ten laboratory isolates of Pseudomonas aeruginosa PAO1. J. Bacteriol. 201, e00595–00518 (2019).
20. Klockgether, J. et al. Genome diversity of Pseudomonas aeruginosa PA01 laboratory strains. J. Bacteriol. 192, 1113–1121 (2010).
21. Jacobs, M. A. et al. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 100, 14339–14344 (2003).
22. Gallagher, L. A., Shendure, J. & Manolc, C. Genome-scale identification of resistance functions in Pseudomonas aeruginosa using Tn-seq. MBio 2, e00315–00310 (2011).
23. Murray, J. L., Kwon, T., Marcutte, E. M. & Whiteley, M. Intrinsic antimicrobial resistance determinants in the superbug Pseudomonas aeruginosa. mBio 6, e01603–e01615 (2015).
24. Lee, S. A. et al. General and condition-specific essential functions of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 112, 5189–5194 (2015).
25. Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L. & Whiteley, M. Essential genes of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc. Natl. Acad. Sci. USA 112, 4110–4115 (2015).
26. Poulsen, B. E. et al. Defining the core essential genome of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 116, 10072–10080 (2019).
27. Gray, A. N. et al. High-throughput bacterial functional genomics in the sequencing era. Curr. Opin. Microbiol. 27, 86–95 (2015).
28. Goodwin, S., McPherson, J. D. & McBee, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333–351 (2016).
29. Schmid, M. et al. Pushing the limits of de novo genome assembly for complex prokaryotic genomes harboring very long, near identical repeats. Nucleic Acids Res. 46, 8953–8965 (2018).
30. Schmid, M. et al. Comparative genomics of completely sequenced Lactobacillus helveticus Genomes provides insights into strain-specific genes and resolves metagenomics data down to the strain level. Front. Microbiol. 9, 63 (2018).
31. Omasits, U. et al. An integrative strategy to identify the entire protein coding potential of prokaryotic genomes by proteogenomics. Genome Res. 27, 2083–2095 (2017).
32. Olivas, A. D. et al. Intestinal tissues induce an SNP mutation in Pseudomonas aeruginosa that enhances its virulence: possible role in anastomotic leak. PLoS ONE 7, e44226 (2012).
33. Winsor, G. L. et al. Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database. Nucleic Acids Res. 44, D646–D653 (2016).
34. Ross, M. G. et al. Characterizing and measuring bias in sequence data. Genome Biol. 14, R51 (2013).
35. Manz, B., Volke, F., Goll, D. & Horn, H. Measuring local floor velocities and biomass structure in biofilm systems with magnetic resonance imaging (MRI). Biotechnol. Bioeng. 84, 424–432 (2003).
36. MacCallum, N. et al. Liquid-infused silicone as a biofouling-free medical material. ACS Biomater. Sci. Eng. 1, 43–51 (2014).
37. Nishiyto, Y., Haas, D. & Itoh, Y. The CbrA-CbrB two-component regulatory system mediates the utilization of multiple carbon and nitrogen sources in Pseudomonas aeruginosa. Mol. Microbiol. 40, 917–931 (2001).
38. Clarke, D. M., Loo, T. W., Gillam, S. & Bragg, P. D. Nucleotide sequence of the pntA and pntB genes encoding the pyridine nucleotide transhydrogenase of Escherichia coli. Eur. J. Biochem. 158, 647–653 (1986).
39. Colvin, K. M. et al. The Pel and Pil polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm matrix. Environ. Microbiol. 14, 1913–1928 (2012).
40. Goodman, A. L. et al. A signaling network reciprocally regulates genes associated with polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol. Microbiol. 50, 205–217 (2003).
41. Filoux, A., Hackani, C. & Haas, D. Isochorismate synthase, the first and rate-limiting enzyme in salicylate biosynthesis of Pseudomonas aeruginosa. J. Biol. Chem. 278, 16893–16898 (2003).
42. Kang, D. & Krienck, N. V. Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosa. J. Microbiol. 56, 449–457 (2018).
43. Opi, E. & Ahrens, C. H. PeptideClassifier for protein inference and targeted quantitative proteomics. Nat. Biotechnol. 28, 647–650 (2010).
44. Filloux, A. & Bleves, S. The bacterial type VI secretion machine: yet another player for protein transport across membranes. Bioeng. 14, 6403–6405 (2002).
45. Fraser, C. M., Eisen, J. A., Nelson, K. E., Paulsen, I. T. & Salzberg, S. L. The value of complete microbial genome sequencing (you get what you pay for). J. Bacteriol. 184, 6403–6405 (2002).
46. De Vrieze, M. et al. Linking comparative genomics of nine potato-associated pseudomonas isolates with their differing biocontrol potential against late blight. Front. Microbiol. 11, 857 (2020).
47. Ghequire, M. G. K. & Ozturk, B. A colicin M-type bacteriocin from Pseudomonas aeruginosa targeting the HoxC heme receptor requires a novel immunity partner. Appl. Environ. Microbiol. 84, https://doi.org/10.1128/AEM.00716-18 (2018).
48. Page, R. & Peti, W. Toxin-antitoxin systems in bacterial growth arrest and persistence. Nat. Chem. Biol. 12, 208–214 (2016).
49. Klausen, M. et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol. Microbiol. 48, 1511–1524 (2003).
50. Weiss Nielsen, M., Sternberg, C., Molin, S. & Regenberg, B. Pseudomonas aeruginosa and Saccharomyces cerevisiae biofilm in cells. J. Vis. Exp. https://doi.org/10.3791/2383 (2011).
51. Yeung, A. T., Bains, M. & Hancock, R. E. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J. Bacteriol. 193, 918–931 (2011).
52. Dietrich, L. E. et al. Bacterial community morphogenesis is intimately linked to the intracellular redox state. J. Bacteriol. 195, 1371–1380 (2013).
53. Jiang, F. et al. The Pseudomonas aeruginosa Type VI secretion PGAP1-like effector induces host autophagy by activating endoplasmic reticulum stress. Cell Rep. 16, 1502–1509 (2016).
54. Cheng, Y. et al. Population dynamics and transcriptomic responses of Pseudomonas aeruginosa in a complex laboratory microbial community. NPJ Biofilms Biomater. 5, 1 (2019).
55. Varadarajan, A. R. et al. A proteogenic resource enabling integrated analysis of listeria genotype-proteotype-phenotype relationships. J. Proteome Res. 19, 1647–1662 (2020).
56. Hood, R. D. et al. A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria. Cell Host Microbe 7, 25–37 (2010).
57. Storz, G., Wolf, Y. I. & Ramamurthi, K. S. Small proteins can no longer be ignored. Annu. Rev. Biochem. 83, 753–777 (2014).
58. Impens, F. et al. N-terminomics identifies PrlR42 as a membrane miniprotein conserved in Firmicutes and critical for stressosome activation in Listeria monocytogenes. Nat. Microbiol. 2, 17005 (2017).
59. Omasits, U. et al. Directed shotgun proteomics guided by saturated RNA-seq identifies a complete expressed prokaryotic proteome. Genome Res. 23, 1516–1527 (2013).
60. Chin, C. S. et al. Nonhybrid, finish microbial genome assemblies from long-read SMRT sequencing data. Nat. Methods 10, 563–569 (2013).
61. Somerville, V. et al. Long-read based assembly of low-complexity metagenome samples results in finished genomes and reveals insights into strain diversity and an active phage system. BMC Microbiol. 19, 143 (2019).
62. Okonechonkov, K., Conesa, A. & Garcia-Alcalde, F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32, 292–294 (2016).
63. Sledzialek, F. J. et al. Accurate detection of complex structural variations using single-molecule sequencing. Nat. Methods 15, 461–468 (2018).
64. Bankevich, A. et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J. Comput. Biol. 19, 455–477 (2012).
ACKNOWLEDGEMENTS

We thank Jürg Frey and Daniel Frei (Agroscope) for generating Illumina MiSeq data. The authors acknowledge funding from the Joint Programming Initiative on AntiMicrobial Resistance (JPIAMR) and national grants to J.S.W. for R.N.A. (MRC MR/R005621/1), HvvdM for OCO (ZonMW grant #547001003), Q.R. and M.T.B. for J.V. (SNSF grant 40AR40_173611), and to F.S. for F.P. (BMBF #01KI1710). C.H.A. acknowledges funding for A.R.V. through grants 15620 and 197391 from the SNSF. J.S.W. and R.N.A. would also like to thank Mark Willett and the Southampton Imaging and Microscopy Centre for support in performing biofilm imaging.

AUTHOR CONTRIBUTIONS

V.S. and A.R.V. carried out genome assembly. A.R.V. performed comparative genomics analyses, remapped existing Tn-seq data, created the iPtgxDB, performed proteogenomics analyses, and created figures with C.H.A. M.T.B. grew cells and extracted gDNA. J.D.P.V. devised and carried out the screening approach, overseen by Q.R. O.C.O. and H.C.v.d.M. designed the mold for the microfluidic flow chamber and J.W. provided device replication expertise. Microfluidic-confined biofilm growth and confirmed reproducibility were undertaken by R.N.A., J.S.W., O.C.O., H.C.v.d.M., F.P., and F.S. P.S. generated shotgun proteomics data from planktonic and biofilm cells provided by R.N.A. R.N.A. and J.S.W. carried out biofilm growth in the mold for selected mutants from the transposon mutant collection and analyzed proteomics data. C.H.A. oversaw genome sequencing and assembly, comparative genomics and proteogenomics, and wrote the manuscript together with input from R.N.A., F.S., J.V., A.R.V., and all other authors. A.R.V., R.N.A., and J.D.P.V. share co-first authorship.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41552-020-00154-8.

Correspondence and requests for materials should be addressed to A.R.V. or C.H.A.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020